<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04755894</url>
  </required_header>
  <id_info>
    <org_study_id>HT-013-01</org_study_id>
    <nct_id>NCT04755894</nct_id>
  </id_info>
  <brief_title>HDDO-1756 Bio Equivalence Study</brief_title>
  <official_title>A Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetic Characteristics After Administration of Fixed-dose Combination of HDDO-1756 or Loose Combination of HDDO-17561/HDDO-17562 in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hyundai Pharmaceutical Co., LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hyundai Pharmaceutical Co., LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For healthy adult volunteers, safety and pharmacokinetic properties are compared between the&#xD;
      two formulations in the case of HDDO-1756 alone administration and HDDO-17561/HDDO-17562&#xD;
      combined administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 12, 2020</start_date>
  <completion_date type="Actual">July 27, 2020</completion_date>
  <primary_completion_date type="Actual">June 19, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetic evaluation variables</measure>
    <time_frame>0~96 hours</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pharmacokinetic evaluation variables</measure>
    <time_frame>0~96 hours</time_frame>
    <description>AUC</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Hyperlipidemias</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HDDO-1756</intervention_name>
    <description>single dose</description>
    <arm_group_label>group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HDDO-17561/HDDO-17562</intervention_name>
    <description>single dose</description>
    <arm_group_label>group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult volunteers aged 19 or older during screening&#xD;
&#xD;
          2. A person who weighs more than 50.0 kg and has a BMI of 18.0 kg/m2 or less and 30.0&#xD;
             kg/m2 or less.&#xD;
&#xD;
             â˜ž BMI (kg/m2) = Weight (kg) / {Long (m)}2&#xD;
&#xD;
          3. A person who has no chronic disease or medical treatment and has no pathological&#xD;
             symptoms or findings as a result of an internal examination;&#xD;
&#xD;
          4. A person who has been determined to be eligible for a clinical trial according to the&#xD;
             characteristics of the drug during screening, such as serum tests, hematologic tests,&#xD;
             hematological tests, urine tests, urine tests, etc. and vital signs (physical tests)&#xD;
             and 12-lead ECG tests.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current or past history of clinically significant liver, kidney, nervous system,&#xD;
             respiratory system, endocrine system, blood and tumor, urinary system, cardiovascular&#xD;
             system, digestive system, musculoskeletal disease, or mental illness, as well as those&#xD;
             with the following symptoms or history:&#xD;
&#xD;
          2. Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency,&#xD;
             or glucose-galactose malabsorption&#xD;
&#xD;
          3. Persons with a history of gastrointestinal diseases (cron disease, ulcer, acute or&#xD;
             chronic pancreatitis, etc.) or gastrointestinal surgery (except simple appendectomy or&#xD;
             hernia surgery) that may affect the absorption of drugs;&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hyundai Pharm</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 8, 2021</study_first_submitted>
  <study_first_submitted_qc>February 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

